Related references
Note: Only part of the references are listed.Harnessing cytokines and chemokines for cancer therapy
David J. Propper et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
Diyuan Xue et al.
SCIENCE IMMUNOLOGY (2022)
Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages
Hamidreza Ebrahimiyan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2022)
Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
Weixiang Zhong et al.
FRONTIERS IN IMMUNOLOGY (2022)
Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21
Cesare Di Nitto et al.
ANTIBODIES (2022)
The dawn of precision medicine in diffuse-type gastric cancer
Akira Ooki et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)
Engineering IL-2 for immunotherapy of autoimmunity and cancer
Rosmely Hernandez et al.
NATURE REVIEWS IMMUNOLOGY (2022)
An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade
Hongchuan Liu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
U. Sahin et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Biological effects of IL-15 on immune cells and its potential for the treatment of cancer
Shuling Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
Ying Li et al.
NATURE COMMUNICATIONS (2021)
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+gastroesophageal adenocarcinoma
Florian Lordick et al.
GASTRIC CANCER (2021)
The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy
Shaoxian Wu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Cytokines in the Treatment of Melanoma
Salah-Eddine Bentebibel et al.
CURRENT ONCOLOGY REPORTS (2021)
Immunoengineering approaches for cytokine therapy
Aslan Mansurov et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2021)
Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
Jingya Guo et al.
CELL RESEARCH (2021)
Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein α Variant with Balanced Safety and Effectiveness, from a Targeted Epitope Mammalian Cell-Displayed Antibody Library
Zhihong Wang et al.
MOLECULAR PHARMACOLOGY (2021)
High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library
Hao Liu et al.
ENGINEERING (2021)
Biological bases of cancer immunotherapy
Maryanne M. Gonzales Carazas et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2021)
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
Wenxiu Wang et al.
CANCER LETTERS (2020)
Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+T Cell Function and Anti-tumor Immunity
Shanling Shen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
A. Arnold et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
The drug treatment research of gastrointestinal cancer in China
Chao Ren et al.
EJSO (2020)
Immune checkpoint inhibitors in cancer immunotherapy
Megan E. Himmel et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)
IL-18: throwing off the shackles to boost anti-tumor immunity
Karen O. Dixon et al.
CELL RESEARCH (2020)
Cytokines in the Treatment of Cancer
Kevin C. Conlon et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer
Hua Jiang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer
Hua Jiang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
O. Tuereci et al.
ANNALS OF ONCOLOGY (2019)
Cytokines in clinical cancer immunotherapy
Pedro Berraondo et al.
BRITISH JOURNAL OF CANCER (2019)
Delivery technologies for cancer immunotherapy
Rachel S. Riley et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Characterization of zolbetuximab in pancreatic cancer models
Oezlem Tuereci et al.
ONCOIMMUNOLOGY (2019)
Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library
Longlong Luo et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
The Common Cytokine Receptor. Chain Family of Cytokines
Jian-Xin Lin et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
Ugur Sahin et al.
EUROPEAN JOURNAL OF CANCER (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Prabhsimranjot Singh et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity
Shruti Bhatt et al.
BLOOD (2017)
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
Stefan Woell et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer
Patrick Micke et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Preclinical Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Interleukin-21 in Cynomolgus Macaques (Macaca fascicularis)
Kimberly S. Waggie et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2012)
Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies
Mark F. Maurer et al.
MABS (2012)
Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma
Mehmood H. Hashmi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)